January 22, 2018 / 2:10 PM / Updated 7 minutes ago BRIEF-Ligand Enters Into Worldwide Omniab Platform License Agreement With Ferring Pharmaceuticals Reuters Staff 
Jan 22 (Reuters) - Ligand Pharmaceuticals Inc: 
* LIGAND ENTERS INTO WORLDWIDE OMNIAB® PLATFORM LICENSE AGREEMENT WITH FERRING PHARMACEUTICALS 
* LIGAND PHARMACEUTICALS INC - ‍UNDER LICENSE, FERRING WILL BE ABLE TO USE FULL OMNIAB PLATFORM TO DISCOVER FULLY HUMAN MONO- AND BISPECIFIC ANTIBODIES​ 
* LIGAND PHARMACEUTICALS INC - ‍FERRING WILL BE RESPONSIBLE FOR ALL COSTS RELATED TO PROGRAMS​ 
* LIGAND PHARMACEUTICALS-WITH DEAL WITH FERRING, CO‍ ELIGIBLE TO RECEIVE ANNUAL PLATFORM ACCESS PAYMENTS, DEVELOPMENT AND REGULATORY MILESTONE PAYMENTS​ Source text for Eikon: Further company coverage: